The global lateral flow assays market size was estimated at USD 9.85 billion in 2024 and is projected to reach USD 13.60 billion by 2030, growing at a CAGR of 5.99% from 2025 to 2030. Lateral flow assays are diagnostic tools that enable the detection of specific target components in liquid samples. One of the key advantages of LFAs is that they do not require costly or specialized laboratory equipment, making them highly accessible for rapid testing in various settings.

A primary factor driving the expansion of this market is the increasing prevalence of infectious diseases globally. The widespread occurrence of these diseases creates an urgent demand for innovative and efficient diagnostic techniques that facilitate timely and effective treatment, ultimately aiming to reduce mortality rates. The COVID-19 pandemic particularly underscored the importance of rapid, accessible diagnostic methods, significantly accelerating the demand for lateral flow assays. However, the need for such diagnostic solutions extends beyond COVID-19, as other infectious disease threats continue to emerge and pose challenges worldwide.

For example, in 2025, an infection with a highly pathogenic avian influenza A (H5N1) virus was reported in Louisiana, USA, resulting in a fatal case. This incident occurred despite the affected individual using personal protective equipment, which was later considered insufficient. The Centers for Disease Control and Prevention (CDC) has indicated that while the overall risk to the general public remains low, certain groups such as farmers, veterinarians, and staff working in wildlife facilities who have close contact with infected animals remain highly vulnerable to infection.

In 2024, there were 67 confirmed human cases of avian influenza, with 40 cases linked to exposure to dairy cattle and 23 associated with poultry farms. In anticipation of potential outbreaks and to minimize risks, the United Kingdom took proactive measures by securing 5 million doses of the H5 vaccine in preparation for the year 2025. This move reflects the ongoing global effort to mitigate infectious disease risks through preventive measures and enhanced diagnostic capabilities.

Key Market Trends & Insights:

• From a regional perspective, North America emerged as the leading market in terms of revenue generation in 2024. This region accounted for the largest share of the total market revenue, reflecting its strong infrastructure, advanced healthcare systems, and high adoption rate of innovative diagnostic technologies.

• Looking at the market on a country-specific level, the United States is anticipated to exhibit the highest compound annual growth rate (CAGR) during the forecast period from 2025 to 2030. This suggests that the U.S. market will grow faster than other countries, driven by factors such as increased healthcare spending, growing awareness about early disease detection, and continuous technological advancements in lateral flow assay products.

• When examining the market by product category, the kits and reagents segment held the largest market share in 2024, accounting for 35.43% of the overall market. This significant share highlights the essential role that diagnostic kits and reagents play in the lateral flow assay process, as they provide the necessary components to perform accurate and reliable tests.

• In terms of application, the clinical testing segment dominated the market, reflecting the widespread use of lateral flow assays in clinical diagnostics. This dominance is due to the critical need for rapid and accessible testing methods in hospitals, laboratories, and other healthcare settings to aid in disease diagnosis, monitoring, and management.

Order a free sample PDF of the Lateral Flow Assays Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 9.85 Billion

• 2030 Projected Market Size: USD 13.60 Billion

• CAGR (2025-2030): 5.99%

• North America: Largest market in 2024

Key Companies & Market Share Insights:

Key players leading the lateral flow assays market include well-established companies such as Abbott Laboratories, Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche AG, Bio-Rad Laboratories, Inc., among others. These companies are actively engaged in the research and development of innovative products and testing kits to meet the growing demand for rapid and reliable diagnostic solutions.

For example, in July 2021, Abbott Laboratories introduced the Panbio COVID-19 Antigen Self-Test. This product is specifically designed to detect the presence of the SARS-CoV-2 virus, the causative agent of COVID-19, in both adults and children. Importantly, this test can be used regardless of whether the individual is showing symptoms, thereby supporting broader testing capabilities.

The launch aligns with the latest advisory from the Indian Council of Medical Research (ICMR) regarding self-testing protocols. These antigen self-test kits were made available with the aim to significantly enhance testing accessibility and capacity, facilitating timely identification not only of symptomatic individuals but also of asymptomatic carriers and close contacts of confirmed COVID-19 cases. This development represents a crucial step towards controlling the spread of the virus through efficient and widespread testing.

Key Players

• Abbott

• Bio-Rad Laboratories, Inc

• Siemens Healthineers AG

• BIOMÉRIEUX

• BD

• QIAGEN

• QuidelOrtho Corporation

• F. Hoffmann-La Roche

• DH Life Sciences, LLC.

• Quest Diagnostics

• Qiagen N.V.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The global lateral flow assays (LFA) market is experiencing significant growth, driven by the increasing prevalence of infectious diseases and the demand for rapid, accessible diagnostic tools. North America led the market in 2024, with the U.S. projected to register the highest compound annual growth rate (CAGR) from 2025 to 2030. The kits and reagents segment held the largest market share in 2024, while the clinical testing application dominated the market. Technological advancements and strategic initiatives by leading players are expected to further propel market growth during the forecast period.